Phase 2 study results of Ionis’ novel antisense treatment for hereditary angioedema to be presented at ACAAI annual meeting
CARLSBAD, Calif., Nov. 7, 2021 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in RNA-targeted therapies, announced today that positive results from the Phase 2 study of its investigational antisense medicine, donidalorsen (formerly IONIS-PKK-LRx), will be presented…
Comments Off on Phase 2 study results of Ionis’ novel antisense treatment for hereditary angioedema to be presented at ACAAI annual meeting